At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
Cannabidioldrug
Likely dose
Cannabidiol 5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome: A Phase II Trial
In Brief
A Phase 2 clinical trial evaluating Cannabidiol for Sturge-Weber Syndrome. Completed, enrolled 11 participants across 1 site.
Detailed Summary
The purpose of this study is to better understand the utility of cannabidiol (CBD/ Epidiolex) for improving the treatment of cognitive impairments in Sturge-Weber syndrome (SWS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSturge-Weber Syndrome
CountriesUnited States
CollaboratorsJazz Pharmaceuticals, Faneca 66 Foundation
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartOct 2019
First PostedJun 2020
Primary CompletionAug 2021
Study CompletionDec 2022
TodayJul 2026
First PostedJun 25, 2020
Enrollment StartOct 14, 2019
Primary CompletionAug 16, 2021
Study CompletionDec 9, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.0 years ago
Interventions
Cannabidioldrug
Initiation of treatment will begin with 5 mg/kg/day given in two divided doses. The dose will be increased by 5 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 20 mg/kg/day given.